<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02096965</url>
  </required_header>
  <id_info>
    <org_study_id>11-001780</org_study_id>
    <nct_id>NCT02096965</nct_id>
  </id_info>
  <brief_title>Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study</brief_title>
  <official_title>Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators propose to use a daily dose of 45 mg (30 mg at 8 AM and 15 mg
      at 4 PM). This relatively small well-tolerated dose is likely to persistently increase urine
      volume and reduce urine supersaturation and to be well tolerated by patients with kidney
      stone disease and normal renal function (see below). The twice-daily (8 AM and 4 PM) regimen
      is designed to produce a maximal AVP inhibition on waking with a gradual fall-off of effect
      during the night. To this end, a higher dose is used in the morning, with a lower dose in the
      afternoon.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urinary calcium oxalate supersaturation (SS)</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Calcium oxalate (CaOx) SS is primary endpoint for CaOx stone formers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Calcium phosphate SS</measure>
    <time_frame>Baseline to three weeks</time_frame>
    <description>Calcium phosphate (CaPhos) SS is the primary endpoint for CaPhos stone formers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Nephrolithiasis, Calcium Oxalate</condition>
  <condition>Nephrolithiasis, Calcium Phosphate</condition>
  <arm_group>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).</description>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive daily dose at 8 AM and at 4 PM.</description>
    <arm_group_label>Tolvaptan first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Tolvaptan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of calcium oxalate or calcium phosphate stone.

          -  Good renal function

        Exclusion Criteria:

          -  History of hypo-or hypernatremia.

          -  History of hypotension or orthostatic dizziness.

          -  Clinical history of congestive heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lieske, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2014</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John Lieske</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Calcium oxalate</keyword>
  <keyword>Calcium phosphate</keyword>
  <keyword>Kidney stone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

